atezolizumab

CHEBI:CHEBI_751314

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
atezolizumab and hyaluronidase-tqjs
rxcui
2693899
pharm_class
Antibodies [CS]
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20241231
dosage_form
LIQUID
route
INTRAVENOUS
marketing_category
DRUG FOR FURTHER PROCESSING
marketing_start_date
20160508
package_marketing_start_date
18-MAY-16
nui
M0001352
pharm_class_cs
Antibodies [CS]
active_ingredient_strength
1875 mg/15mL
labeler_name
F. Hoffmann-La Roche AG
manufacturer_name
Genentech, Inc.
active_ingredient_name
ATEZOLIZUMAB
unii
52CMI0WC3Y
pharm_class_epc
Programmed Death Receptor-1 Blocking Antibody [EPC]
product_ndc
50242-933
spl_id
43d228ed-bd2f-4cb2-b11c-062f4f449ba5
package_ndc
50242-933-86
package_description
1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VIAL, SINGLE-DOSE
pharm_class_moa
Programmed Death Receptor-1-directed Antibody Interactions [MoA]
brand_name
Tecentriq Hybreza
brand_name_base
Tecentriq Hybreza
application_number
BLA761347
spl_set_id
a617b089-ce66-464b-987b-b45d029b4d6f
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class